Paper41459511
Conceptual quantitative systems pharmacology framework for supporting clinical trial design in organ-specific autoimmune and rare diseases.
Sun Z and 2 others. Front Immunol, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Conceptual quantitative systems pharmacology framework for supporting clinical trial design in organ-specific autoimmune and rare diseases. Papers, record 41459511. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41459511
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Conceptual quantitative systems pharmacology framework for supporting clinical trial design in organ-specific autoimmune and rare diseases.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Rare Diseases | Major topic |
| Autoimmune Diseases | Major topic |
| Clinical Trials as Topic | Major topic |
| Humans | |
| Research Design | |
| Bayes Theorem | |
| Systems Biology | |
| Organ Specificity | |
| Computer Simulation | |
| Drug Development |
Source PubMed
References63
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35352835 | Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus. | J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/35352835 | PubMed |
| 2 | 35260419 | Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. | J Am Soc Nephrol | 2022 | https://conductscience.org/library/papers/35260419 | PubMed |
| 3 | 26212387 | Human autoimmune diseases: a comprehensive update. | J Intern Med | 2015 | https://conductscience.org/library/papers/26212387 | PubMed |
| 4 | 36001711 | Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36001711 | PubMed |
| 5 | 31161268 | Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices. | AAPS J | 2019 | https://conductscience.org/library/papers/31161268 | PubMed |
| 6 | 25502178 | A modified murine model of systemic sclerosis: bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis. | Lab Invest | 2015 | https://conductscience.org/library/papers/25502178 | PubMed |
| 7 | 37898164 | Physiological Indirect Response Model to Omics-Powered Quantitative Systems Pharmacology Model. | J Pharm Sci | 2024 | https://conductscience.org/library/papers/37898164 | PubMed |
| 8 | 32620589 | Ultra-rare disease: an European perspective. | Eur Respir Rev | 2020 | https://conductscience.org/library/papers/32620589 | PubMed |
| 9 | 37146963 | Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trials. | Drug Discov Today | 2023 | https://conductscience.org/library/papers/37146963 | PubMed |
| 10 | 30667172 | Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network. | CPT Pharmacometrics Syst Pharmacol | 2019 | https://conductscience.org/library/papers/30667172 | PubMed |
| 11 | 37809085 | A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis. | Front Immunol | 2023 | https://conductscience.org/library/papers/37809085 | PubMed |
| 12 | 39632463 | Quantitative Systems Pharmacology-Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease. | Clin Pharmacol Ther | 2025 | https://conductscience.org/library/papers/39632463 | PubMed |
| 13 | 39771538 | The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39771538 | PubMed |
| 14 | 30123942 | Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/30123942 | PubMed |
| 15 | 39062600 | Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases. | Genes (Basel) | 2024 | https://conductscience.org/library/papers/39062600 | PubMed |
| 16 | 30697975 | Reproducibility of Quantitative Systems Pharmacology Models: Current Challenges and Future Opportunities. | CPT Pharmacometrics Syst Pharmacol | 2019 | https://conductscience.org/library/papers/30697975 | PubMed |
| 17 | 27761201 | The promises of quantitative systems pharmacology modelling for drug development. | Comput Struct Biotechnol J | 2016 | https://conductscience.org/library/papers/27761201 | PubMed |
| 18 | 37984065 | Creating a Roadmap to Quantitative Systems Pharmacology-Informed Rare Disease Drug Development: A Workshop Report. | Clin Pharmacol Ther | 2024 | https://conductscience.org/library/papers/37984065 | PubMed |
| 19 | 31529677 | A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins. | CPT Pharmacometrics Syst Pharmacol | 2019 | https://conductscience.org/library/papers/31529677 | PubMed |
| 20 | 40743487 | Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. | Neurol Neuroimmunol Neuroinflamm | 2025 | https://conductscience.org/library/papers/40743487 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42812715 | Anti-CD19 CAR T-cell therapy for autoimmune diseases: from exploratory clinical trials to quantitative pharmacodynamic modeling development. | Front Immunol | 2026 | https://conductscience.org/library/papers/42812715 | PubMed |
| 42080091 | Neural-immune-cancer crosstalk in pancreatic cancer: mechanisms and clinical translation. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42080091 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41459511
GET https://conductscience.org/api/papers/v1/41459511/references?page=2